Pharmaxon SA
This article was originally published in Start Up
Executive Summary
Pharmaxon aims to control cell mobility to fight disorders of the central nervous system and cancer. For glioblastoma, it has developed a neural cell mobility inhibitor that blocks cell migration in vitro and limits glioblastoma proliferation in animal models.
You may also be interested in...
Start-Up Previews (07/2008)
A preview of the emerging health care companies profiled in the current, all-profiles issue of Start-Up. This month's profile groups are "Glioblastoma Start-Ups Get Specific," "Glaucoma Start-Ups Reach Critical Mass," and "ALS on the Cusp." Plus these Start-Ups Across Health Care: EarlySense, NeoChord, and Pantec Biosolutions.
MedGenesis Therapeutix Inc.
MedGenesis Therapeutix is developing convection-enhanced delivery, a technique that involves infusion under positive pressure of a drug to specific locations of the brain. The leading indication for its CED technology is glioblastoma.
Traversa Therapeutics Inc
Traversa aims to solve a fundamental problem: the adequate delivery of short interfering RNA molecules to a wide range of cell types via a non-cytoxic mechanism.